MX2016012168A - Formulacion adyuvante no toxica que comprende una composicion de liposoma que contiene monofosforil-lipido a (mpla) y una saponina. - Google Patents
Formulacion adyuvante no toxica que comprende una composicion de liposoma que contiene monofosforil-lipido a (mpla) y una saponina.Info
- Publication number
- MX2016012168A MX2016012168A MX2016012168A MX2016012168A MX2016012168A MX 2016012168 A MX2016012168 A MX 2016012168A MX 2016012168 A MX2016012168 A MX 2016012168A MX 2016012168 A MX2016012168 A MX 2016012168A MX 2016012168 A MX2016012168 A MX 2016012168A
- Authority
- MX
- Mexico
- Prior art keywords
- mol
- saponin
- liposome composition
- mpla
- adjuvant formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 239000002671 adjuvant Substances 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000002502 liposome Substances 0.000 title abstract 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 title abstract 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 title abstract 3
- 229930182490 saponin Natural products 0.000 title abstract 3
- 150000007949 saponins Chemical class 0.000 title abstract 3
- 231100000252 nontoxic Toxicity 0.000 title 1
- 230000003000 nontoxic effect Effects 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 239000000232 Lipid Bilayer Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 231100000324 minimal toxicity Toxicity 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461970118P | 2014-03-25 | 2014-03-25 | |
| PCT/US2015/022461 WO2015148648A1 (en) | 2014-03-25 | 2015-03-25 | Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016012168A true MX2016012168A (es) | 2017-04-25 |
Family
ID=52829375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016012168A MX2016012168A (es) | 2014-03-25 | 2015-03-25 | Formulacion adyuvante no toxica que comprende una composicion de liposoma que contiene monofosforil-lipido a (mpla) y una saponina. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10434167B2 (enExample) |
| EP (1) | EP3122380B1 (enExample) |
| JP (1) | JP6608422B2 (enExample) |
| KR (1) | KR102242875B1 (enExample) |
| CN (1) | CN107124869B (enExample) |
| AU (1) | AU2015236106A1 (enExample) |
| CA (1) | CA2943190A1 (enExample) |
| MX (1) | MX2016012168A (enExample) |
| RU (1) | RU2016141622A (enExample) |
| SG (2) | SG10201808315UA (enExample) |
| WO (1) | WO2015148648A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109152361A (zh) * | 2016-03-09 | 2019-01-04 | 技术研究及发展基金有限公司 | 脂质体制剂及在农业中使用该脂质体制剂的方法 |
| JP6661454B2 (ja) * | 2016-04-21 | 2020-03-11 | 株式会社東海理化電機製作所 | 表示装置、表示板の製造方法 |
| WO2018200645A1 (en) * | 2017-04-25 | 2018-11-01 | Adjuvance Technologies, Inc. | Triterpene saponin analogues |
| EP3615005B1 (en) * | 2017-04-28 | 2025-07-30 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Compositions and methods for vaccine delivery |
| CN107669692B (zh) * | 2017-09-07 | 2020-09-29 | 中国人民解放军第二军医大学 | Mpla在制备电离辐射致肠道损伤防治药物中的应用 |
| CA3078223A1 (en) * | 2017-09-08 | 2019-03-14 | Infectious Disease Research Institute | Liposomal formulations comprising saponin and methods of use |
| WO2020243166A1 (en) * | 2019-05-28 | 2020-12-03 | The Regents Of The University Of California | Th1-polarizing adjuvants for enhancing immunogenicity of hiv antigens |
| CN110613844B (zh) * | 2019-10-23 | 2024-02-27 | 中国医学科学院生物医学工程研究所 | 一种迷你联合佐剂纳米颗粒及其制备方法和应用 |
| AU2020407871A1 (en) | 2019-12-20 | 2022-06-30 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof |
| EP3892296A1 (en) * | 2020-04-07 | 2021-10-13 | InnoMedica Holding AG | Immunogenic composition comprising an antigenic moiety and a liposomal formulation, method of producing the composition, the composition for use as a medicament, in particular for use as a vaccine |
| WO2022003443A1 (ko) * | 2020-06-30 | 2022-01-06 | 아이진 주식회사 | 양이온성 리포좀을 포함하는 사포닌의 용혈 억제용 조성물 |
| GB2600468A (en) * | 2020-10-30 | 2022-05-04 | Excivion Ltd | Adjuvant composition |
| CN112546233A (zh) * | 2020-12-25 | 2021-03-26 | 常州大学 | 一种负载水不溶性免疫调节分子的透明质酸复合材料及其制备方法 |
| CN114366810B (zh) * | 2022-02-15 | 2024-11-22 | 中国人民解放军陆军军医大学 | 一种可高效诱导体液和细胞免疫的天然微生物和植物来源复合双佐剂及其制备方法和应用 |
| US20250177516A1 (en) | 2022-03-14 | 2025-06-05 | Pfizer Inc. | Methods for producing an adjuvant |
| JP2025532724A (ja) | 2022-09-29 | 2025-10-03 | ファイザー・インク | Ｒｓｖ ｆタンパク質三量体を含む免疫原性組成物 |
| IL321069A (en) | 2022-12-01 | 2025-07-01 | Pfizer | Pneumococcal conjugate vaccine preparations |
| IL320955A (en) * | 2022-12-13 | 2025-07-01 | Pfizer | Immunogenic compounds and methods for generating an immune response against CLOSTRIDIIOIDES (CLOSTRIDIUM) DIFCILE |
| WO2025057058A1 (en) * | 2023-09-13 | 2025-03-20 | Pfizer Inc. | Methods for producing an adjuvant |
| TW202527906A (zh) | 2023-09-14 | 2025-07-16 | 美商輝瑞股份有限公司 | 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途 |
| WO2025163460A2 (en) | 2024-01-30 | 2025-08-07 | Pfizer Inc. | Vaccines against respiratory diseases |
| CN117771361B (zh) * | 2024-02-27 | 2024-06-07 | 天津中逸安健生物科技有限公司 | 一种聚肌苷酸-聚胞苷酸复合物的脂质纳米佐剂及其制备方法与应用 |
| WO2025191415A1 (en) | 2024-03-11 | 2025-09-18 | Pfizer Inc. | Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4302459A (en) | 1980-03-19 | 1981-11-24 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in leishmaniasis chemotherapy with 8-aminoquinoline derivatives |
| US5231112A (en) | 1984-04-12 | 1993-07-27 | The Liposome Company, Inc. | Compositions containing tris salt of cholesterol hemisuccinate and antifungal |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| US4684479A (en) | 1985-08-14 | 1987-08-04 | Arrigo Joseph S D | Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures |
| US6759057B1 (en) | 1986-06-12 | 2004-07-06 | The Liposome Company, Inc. | Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs |
| CN1093255A (zh) * | 1986-06-17 | 1994-10-12 | 恩特雷麦德有限公司 | 抗甾醇疫苗 |
| IE60901B1 (en) | 1986-08-21 | 1994-08-24 | Vestar Inc | Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics |
| US6406713B1 (en) | 1987-03-05 | 2002-06-18 | The Liposome Company, Inc. | Methods of preparing low-toxicity drug-lipid complexes |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| AU598958B2 (en) | 1987-11-12 | 1990-07-05 | Vestar, Inc. | Improved amphotericin b liposome preparation |
| US5888519A (en) | 1988-06-02 | 1999-03-30 | The United States Of America As Represented By The Secretary Of The Army | Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections |
| US5215680A (en) | 1990-07-10 | 1993-06-01 | Cavitation-Control Technology, Inc. | Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles |
| EP0761231B1 (en) * | 1992-06-25 | 2000-01-12 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| WO1994014454A1 (en) | 1992-12-29 | 1994-07-07 | Entremed, Inc. | Vaccines against sterols |
| GB9320668D0 (en) * | 1993-10-07 | 1993-11-24 | Secr Defence | Liposomes containing particulare materials |
| US6846489B1 (en) * | 1995-04-25 | 2005-01-25 | Smithkline Beecham Biologicals S.A. | Vaccines containing a saponin and a sterol |
| UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| WO1998007409A1 (en) | 1996-08-23 | 1998-02-26 | Sequus Pharmaceuticals, Inc. | Liposomes containing a cisplatin compound |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| EP0932390A1 (en) | 1996-10-11 | 1999-08-04 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
| NZ336538A (en) | 1996-10-15 | 2001-11-30 | Liposome Co Inc | N-acyl phosphatidylethanolamine-mediated liposomal drug delivery |
| US6231859B1 (en) | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
| GB9817052D0 (en) * | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| CN101711278B (zh) * | 2007-03-01 | 2013-08-14 | 美国天主教大学 | 与基质结合的t4噬菌体 |
| GB0910046D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
| WO2012088414A1 (en) * | 2010-12-23 | 2012-06-28 | Ludwig Institute For Cancer Research Ltd. | Liposomal formulation of nonglycosidic ceramides and uses thereof |
-
2015
- 2015-03-25 EP EP15716264.5A patent/EP3122380B1/en active Active
- 2015-03-25 SG SG10201808315UA patent/SG10201808315UA/en unknown
- 2015-03-25 SG SG11201607396WA patent/SG11201607396WA/en unknown
- 2015-03-25 KR KR1020167026025A patent/KR102242875B1/ko active Active
- 2015-03-25 US US15/127,081 patent/US10434167B2/en active Active
- 2015-03-25 RU RU2016141622A patent/RU2016141622A/ru not_active Application Discontinuation
- 2015-03-25 AU AU2015236106A patent/AU2015236106A1/en not_active Abandoned
- 2015-03-25 CA CA2943190A patent/CA2943190A1/en not_active Abandoned
- 2015-03-25 WO PCT/US2015/022461 patent/WO2015148648A1/en not_active Ceased
- 2015-03-25 JP JP2017502920A patent/JP6608422B2/ja active Active
- 2015-03-25 CN CN201580026334.9A patent/CN107124869B/zh active Active
- 2015-03-25 MX MX2016012168A patent/MX2016012168A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3122380B1 (en) | 2025-03-19 |
| KR20170007242A (ko) | 2017-01-18 |
| CN107124869B (zh) | 2022-04-01 |
| JP2017515889A (ja) | 2017-06-15 |
| US20170182152A1 (en) | 2017-06-29 |
| SG11201607396WA (en) | 2016-10-28 |
| CA2943190A1 (en) | 2015-10-01 |
| KR102242875B1 (ko) | 2021-04-20 |
| SG10201808315UA (en) | 2018-10-30 |
| EP3122380A1 (en) | 2017-02-01 |
| CN107124869A (zh) | 2017-09-01 |
| RU2016141622A (ru) | 2018-04-25 |
| AU2015236106A1 (en) | 2016-10-20 |
| RU2016141622A3 (enExample) | 2018-10-26 |
| JP6608422B2 (ja) | 2019-11-20 |
| US10434167B2 (en) | 2019-10-08 |
| WO2015148648A1 (en) | 2015-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016012168A (es) | Formulacion adyuvante no toxica que comprende una composicion de liposoma que contiene monofosforil-lipido a (mpla) y una saponina. | |
| MX2017003205A (es) | Composiciones antimicrobianas y sus metodos de uso. | |
| AR105401A1 (es) | Mezcla acuosa que comprende un vector adenoviral, composición liofilizada, procedimiento | |
| CL2018001514A1 (es) | Líquido higienizante de superficies en contacto con alimentos | |
| CL2016001287A1 (es) | Benzamidas sustituidas y procedimiento para su uso | |
| CL2014002564A1 (es) | Composiciones para tratamiento de agua que comprende un coagulante que contiene aluminio y un polisacarido no derivado natural, en donde la relacion entre el polisacarido y el coagulante es entre 1:10 hasta 1:100; y métodos de uso. | |
| MX2016014564A (es) | Vacuna contra la acinetobacter baumannii obtenida a partir de componentes celulares carentes de lipopolisacarido. | |
| CL2014001060A1 (es) | Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades. | |
| MX2015001348A (es) | Cocleatos hechos con fosfatidilserina de soja. | |
| PE20151944A1 (es) | Sistema de procesamiento por lotes multiples para la preparacion de una solucion de carbonato hidrogeno de calcio adecuada, para la remineralizacion de agua desalinizada y de agua blanda de origen natural | |
| MX2016011176A (es) | Polipeptidos fhbp meningococicos modificados. | |
| CL2015000608A1 (es) | Formulaciones de daptomicina y usos de la misma | |
| MX2016011358A (es) | Composiciones liquidas de lactasa. | |
| CL2017000715A1 (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo | |
| MX2016016746A (es) | Composiciones de vacuna con adyuvante dual, preparacion y usos. | |
| UY35228A (es) | Composiciones acuosas de cloquintocet-mexilo de temperatura estable | |
| MX2018015439A (es) | Conservacion de microorganismos. | |
| CL2015002488A1 (es) | Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen | |
| MX2017000076A (es) | Macromoleculas estrellas compatibles con tensoactivos. | |
| CO2017001902A2 (es) | Adyuvantes acondicionadores del agua que promueven una baja volatilidad | |
| ECSP17005294A (es) | Composición adhesiva | |
| CL2015000537A1 (es) | Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos. | |
| AR103235A1 (es) | Agente de turbidez a base de almidón para bebidas en polvo | |
| CL2014001127A1 (es) | Metodos y composicion de fumigante que comprende hexafluoropropeno, 1,1,3,3,3-pentafluoropropeno o combinacion de los mismos. | |
| CL2015002324A1 (es) | Método para el tratamiento y control de enfermedades de postrecolección de frutas y hortalizas y composiciones que comprenden extractos naturales y formulaciones fitofortificantes y/o fungicidas para aplicar en dicho método. |